222 related articles for article (PubMed ID: 29884408)
1. The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.
Saloura V; Vougiouklakis T; Sievers C; Burkitt K; Nakamura Y; Hager G; van Waes C
Oral Oncol; 2018 Jun; 81():100-108. PubMed ID: 29884408
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma.
Murali M; Saloura V
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360250
[TBL] [Abstract][Full Text] [Related]
3. Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Farhangdoost N; Horth C; Hu B; Bareke E; Chen X; Li Y; Coradin M; Garcia BA; Lu C; Majewski J
Cell Rep; 2021 Feb; 34(8):108769. PubMed ID: 33626351
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets.
Xu M; Hou Y; Li N; Yu W; Chen L
J Transl Med; 2024 May; 22(1):418. PubMed ID: 38702756
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
Jelinek MJ; Vokes EE
J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
[No Abstract] [Full Text] [Related]
6. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
7. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Sola AM; Johnson DE; Grandis JR
Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
[TBL] [Abstract][Full Text] [Related]
8. Highlights in Head and Neck Cancer.
Chau NG; Tishler RB; Haddad RI
JAMA Oncol; 2017 Apr; 3(4):441-442. PubMed ID: 27893016
[No Abstract] [Full Text] [Related]
9. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in developing selective inhibitors of protein methyltransferases.
Kaniskan HÜ; Jin J
Curr Opin Chem Biol; 2017 Aug; 39():100-108. PubMed ID: 28662389
[TBL] [Abstract][Full Text] [Related]
12. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
14. Disruption of
Bui N; Huang JK; Bojorquez-Gomez A; Licon K; Sanchez KS; Tang SN; Beckett AN; Wang T; Zhang W; Shen JP; Kreisberg JF; Ideker T
Mol Cancer Ther; 2018 Jul; 17(7):1585-1594. PubMed ID: 29636367
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
Bourguignon LY; Wong G; Shiina M
J Biol Chem; 2016 May; 291(20):10571-85. PubMed ID: 27002147
[TBL] [Abstract][Full Text] [Related]
16. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.
Papillon-Cavanagh S; Lu C; Gayden T; Mikael LG; Bechet D; Karamboulas C; Ailles L; Karamchandani J; Marchione DM; Garcia BA; Weinreb I; Goldstein D; Lewis PW; Dancu OM; Dhaliwal S; Stecho W; Howlett CJ; Mymryk JS; Barrett JW; Nichols AC; Allis CD; Majewski J; Jabado N
Nat Genet; 2017 Feb; 49(2):180-185. PubMed ID: 28067913
[TBL] [Abstract][Full Text] [Related]
17. Challenges in profiling and lead optimization of drug discovery for methyltransferases.
Horiuchi KY
Drug Discov Today Technol; 2015 Nov; 18():62-8. PubMed ID: 26723894
[TBL] [Abstract][Full Text] [Related]
18. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
19. Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Wang T; Wang YX; Dong YQ; Yu YL; Ma K
Arch Oral Biol; 2020 May; 113():104711. PubMed ID: 32220804
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation association with stage progression of head and neck squamous cell carcinoma.
Ghafarpour V; Khansari M; Banaei-Moghaddam AM; Najafi A; Masoudi-Nejad A
Comput Biol Med; 2021 Jul; 134():104473. PubMed ID: 34034219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
